Jennifer Berry
Family · Saint Louis, MONPI 1366719072
Payments from drug & device makers
Across 627 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$2K
- Merck$625
- Viiv Healthcare Company$521
- Novo Nordisk$515
- Lilly USA, LLC$514
- plus $5K from 54 others
What the payments were for
- Speaking & faculty fees$841%
- Food & beverage$10,60797%
- Education$2022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,894 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 94 | $404,359 |
| SerostimSomatropin | 13 | $261,326 |
| JulucaDolutegravir/Rilpivirine | 38 | $151,276 |
| OzempicSemaglutide | 85 | $96,487 |
| DovatoDolutegravir Sodium/Lamivudine | 26 | $92,206 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $84,161 |
| TivicayDolutegravir Sodium | 21 | $75,278 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,214 |
| EliquisApixaban | 40 | $24,217 |
| TrulicityDulaglutide | 15 | $18,188 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,292 |
| MounjaroTirzepatide | 12 | $13,156 |
| JardianceEmpagliflozin | 12 | $8,506 |
| XareltoRivaroxaban | 12 | $8,413 |
| ValacyclovirValacyclovir Hcl | 42 | $2,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $1,515 | $488,520110 claims |
| Viiv Healthcare CompanyJuluca, Dovato, Tivicay | $521 | $318,75985 claims |
| EMD Serono, Inc.Serostim | $361 | $261,32613 claims |
| Novo NordiskOzempic | $515 | $96,48785 claims |
| Janssen Products, LPSymtuza | $85 | $60,21413 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $514 | $31,34427 claims |
| PfizerEliquis | $493 | $24,21740 claims |
| GSKTrelegy Ellipta, Arexvy | $77 | $15,69530 claims |
| Boehringer IngelheimJardiance | $31 | $8,50612 claims |
| Johnson & JohnsonXarelto | $314 | $8,41312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Saint Louis
- Rebecca SeabaughSaint Louis$68K
- Jordan PerezSaint Louis$43K
- Lindsay GwaltneySaint Louis$28K
- Sara WoottenSaint Louis$21K
- Kelly RobertsSaint Louis$17K
- Matthew CarySaint Louis$15K
- Philip DudakSaint Louis$14K
- Kenan SahbazSaint Louis$14K
- Nicole CarrSaint Louis$14K
- Ashley GarrettSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.